Interleukin-23

ORLANDO — The American Academy of Dermatology annual meeting was packed with “massive advancements” across the field, Joel M. Gelfand, MD, MSCE, chief medical editor of Healio Dermatology, said.

In this Healio exclusive video, Lawrence F. Eichenfield, MD, discusses oral treatments available to pediatric and adolescent psoriasis discussed at Maui Derm 2025.

Skyrizi significantly improved clinical remission rates as both induction and maintenance therapy vs. placebo in patients with moderately to severely active ulcerative colitis, according to data from the phase 3 INSPIRE and COMMAND trials.

In this video, Uma Mahadevan, MD, director of the Colitis and Crohn’s Disease Center at the University of California, San Francisco, spoke with Healio about a consensus conference on the management of IBD in pregnancy.

In this Healio video, Uma Mahadevan, MD, director of the Colitis and Crohn’s Disease Center at the University of California, San Francisco, discusses new study results assessing the use of interleukin-23 inhibitors in ulcerative colitis.

In this Healio exclusive video, Steven R. Feldman, MD, PhD, discussed psoriasis findings from the FRONTIER-2 study presented at the American Academy of Dermatology Annual Meeting.

SAN DIEGO — In patients with psoriatic arthritis, those with female sex are less likely than those with male sex to achieve outcomes in randomized clinical trials for advanced therapies, according to data presented at ACR Convergence 2023.

Topline findings from the phase 3 VIVID-1 trial showed Eli Lilly’s mirikizumab, an interleukin-23p19 antagonist, demonstrated clinical remission and endoscopic response through 52 weeks in adults with moderate to severe Crohn’s disease.

In this Healio video exclusive, Melodie Young, MSN, RN, ANP-C, discusses highlights in psoriasis from Maui Derm NP+PA.

An oral interleukin-23 receptor antagonist peptide for adults with moderate to severe plaque psoriasis, JNJ-2113, met all endpoints in an efficacy trial and is now advancing to phase 3, according to a press release.